• IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO

    Source: Nasdaq GlobeNewswire / 04 Nov 2021 08:00:03   America/New_York

    NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced presentations at three scientific conferences in November.

    Event:Protein & Antibody Engineering Summit (PEGS) Europe
    Presenter:Lawrence Lamb, Ph.D., Executive Vice President, Chief Scientific Officer and co-founder of IN8bio
    Presentation: A Pivotal Role for Concurrent Chemotherapy and γδ T Cell Therapy (Drug Resistant Therapy – DRI) in the Post-Induction Primary Disease Setting for Reducing the Immunosuppressive Properties of the Tumor Microenvironment
    Date:November 4
    Time:9 a.m. CET
    Location:Hotel Arts Ritz Carleton, Barcelona
      
    Event:Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
    Presenter:Kate Rochlin, Ph.D., Vice President, Operations and Innovation at IN8bio
    Presentation:Poster 158: Chemotherapy Resistant Gamma Delta T-cell Immunotherapy can leverage synergistic ligand expression through combinational chemotherapy and PARP-inhibitor use to enhance tumor cell recognition & killing
    Date:November 13th
    Time:7 to 8:30 p.m. EST
    Location:Walter E. Washington Convention Center, Washington, D.C.
      
    Event:Society for Neuro-Oncology 26th Annual Meeting
    PresenterLei Ding, Ph.D., Staff Scientist – CAR T Lead, IN8bio
    Presentation:Poster: Dual chlorotoxin CAR and MGMT γδ T cells for drug resistant immunotherapy of glioblastoma multiforme
    Date:November 19
    Time:7:30 to 9:30 p.m. EST
    Location:Hynes Convention Center, Boston
      
    Event:Society for Neuro-Oncology 26th Annual Meeting
    Sponsor:IN8bio-sponsored academic research
    Presenter:Anita Hjelmeland, Ph.D., and Amber Jones
    Presentation:Poster: Enhancing Glioblastoma Cell Stress Response to Improve Gamma Delta T-Cell Immunotherapy
    Date:November 19
    Time:7:30 to 9:30 p.m. EST
    Location:Hynes Convention Center, Boston

    About IN8bio
    IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product candidates for solid and liquid tumors. Gamma-delta T-cells are a specialized population of T-cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

    IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.

    For more information about IN8bio and its programs, please visit www.IN8bio.com.

    Company Contact:
    IN8bio, Inc.
    Kate Rochlin, Ph.D.
    +1 646.600.6GDT (6438)
    info@IN8bio.com 

    Investors:
    Solebury Trout
    David Buck
    + 1 646.378.2927
    dbuck@soleburytrout.com 

    Media:
    Burns McClellan, Inc.
    Robert Flamm, Ph.D. / Harrison Wong
    +1 212.213.0006 - ext. 364 / 316
    rflamm@burnsmc.com / hwong@burnsmc.com 


    Primary Logo

Share on,